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Background: Ubiquitination is a reversible process of posttranslational protein modification through the action of
the family of deubiquitylating enzymes which contain ubiquitin-specific protease 9x (USP9X). Recent evidence
indicates that USP9X is involved in the progression of various human cancers. The aim was to detect the expression
of USP9X in the progression from normal epithelium to invasive esophageal squamous cell cancer (ESCC) and
evaluate the relevance of USP9X expression to the tumor progression and prognosis.
Methods: In this study, USP9X immunohistochemical analysis was performed on tissues constructed from ESCC
combined with either normal epithelium or adjacent precursor tissues of 102 patients. All analyses were performed
by SPSS 13.0 software.
Results: We observed that the level of high USP9X expression increased gradually in the transformation from
normal epithelium (4.0%), to low grade intraepithelial neoplasia (10.5%), then to high grade intraepithelial neoplasia
(28.6%), and finally to invasive ESCC (40.2%). The expression of USP9X was found to be significantly different
between the normal mucosa and ESCC (P < 0.001), and between low grade intraepithelial neoplasia and high grade
intraepithelial neoplasia (p = 0.012). However, no difference was observed between the high expression of USP9X in
normal mucosa and low grade intraepithelial neoplasia (P = 0.369), nor between high grade intraepithelial neoplasia
and ESCC (p = 0.115). Interestingly, the most intensive staining for USP9X was usually observed in the basal and
lower spinous layers of the esophageal epithelium with precursor lesions which often resulted in the earliest
malignant lesion. USP9X expression status was positively associated with both depth of invasion (p = 0.046) and
lymph node metastasis (p = 0.032). Increased USP9X expression was significantly correlated to poorer survival rate in
ESCC patients (p = 0.001). When adjusted by multivariate analysis, USP9X expression (HR 2.066, P = 0.005), together
with TNM stage (HR 1.702, P = 0.042) was an independent predictor for overall survival.
Conclusions: Up-regulation of USP9X plays an important role in formation and progression of precancerous lesions
in ESCC and USP9X expression levels were significantly correlated with the survival of ESCC patients. Thus, USP9X
could be considered as a potential biomarker and prognostic predictor for ESCC.
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Esophageal squamous cell cancer (ESCC) is one of the
most common lethal tumors in the world due to advanced
disease, local relapse, distant metastasis, and resistance to
adjuvant therapy [1-3]. Normal esophageal squamous
epithelia undergo both genetic and histological changes
during the evolution of ESCC, which involves a multi-
stage process from noninvasive precursor lesions, ini-
tially containing low grade intraepithelial neoplasia, then
containing high grade intraepithelial neoplasia, and finally
towards invasive carcinoma [4]. Although certain events
have been reported to occur during this process [5,6], the
mechanisms regulating the malignancy and progression of
ESCC remain under investigation [7,8].
Ubiquitination has been found to be a key regulatory
mechanism in multiple biological processes and controls
almost all aspects of protein function through the re-
versible posttranslational modification of cellular pro-
teins by the action of ubiquitylating and deubiquitylating
enzymes (DUBs) [5,9]. More attention has turned to the
wide functional diversity of DUBs because they have a
profound impact on the regulation of multiple biological
processes including cell-cycle control, DNA repair, chro-
matin remodeling and several signaling pathways that
are frequently altered in tumor development [10-12].
Ubiquitin-specific proteases (USPs), the largest group of
DUBs, have fundamental roles in the ubiquitin system
through their ability to specifically deconjugate ubiquitin
from ubiquitylated substrates [13]. USP9X (ubiquitin-
specific protease-9), one member of the USPs family, is
widely expressed in all tissues with a large 2547-amino-
acid-residue [14]. Overexpression of USP9X is reported in
follicular lymphoma, diffuse large B-cell lymphoma and
multiple myeloma [15]. In the same study, increased
USP9X in multiple myeloma patients correlates with poor
survival and the authors conclude that USP9X stabilizes
MCL1, one member of pro-survival BCL2 family, and
promotes tumor cell survival [15]. Afterwards, a partly se-
lective DUB inhibitor WP1130 effectively downregulates
anti-apoptotic and upregulates pro-apoptotic proteins
by blocking the DUB activity including USP9X [5,16].
Moreover, WP1130 has also been found to promote Mcl-
1 degradation and increases tumor cell sensitivity to
chemotherapies in colon adenocarcinomas and lung
cancers [17].
Nevertheless, to our knowledge, no direct evidence of
USP9X in ESCC has been provided so far. The expres-
sion of USP9X and the exact role in the evolution of
ESCC are far from understood. In the present study, we
investigated USP9X expression and its potential clinical
significance in normal esophageal epithelium, ESCC and
its precursor lesions, trying to clarify the possible func-
tion of USP9X in the cancer malignancy, progression
and prognosis.Materials and methods
Tissue sample collection
ESCC combined with normal epithelium or adjacent
precursor lesions from 102 patients were collected in
the Pathology Department of West China Hospital,
Sichuan University from Jan, 2001 to Jan, 2003. Patients
receiving chemotherapy or radiation therapy before
esophagectomy were excluded. Among the 102 patients,
only 25 cases were ESCC combined with normal mucosa.
These 25 had no precursor lesions. Of the remaining 77
cases, there were 20 cases of ESCC combined with low
grade intraepithelial neoplasia, 17 cases were ESCC com-
bined with high grade intraepithelial neoplasia, and 18
cases were ESCC combined with both precursor lesions.
The remaining 22 cases were ESCC with no other compli-
cations. All tumors had been confirmed by postoperative
histopathologic assessment. Staging in esophageal cancer
was principally based on the International Union Against
Cancer Classification of 2010 [18] while evaluation of
tumour differentiation was based on histological cri-
teria of the guidelines of the World Health Organization
Pathological Classification of Tumors. Overall survival
was calculated from the date of surgery to the date of
death or the last follow-up. All patients were followed
until death or the end of the follow-up period (March,
2012).
The study was approved by the ethics committee of
West China Second Hospital of Sichuan University and
informed consent was obtained from all patients under-
going surgery.
Immunohistochemistry
The slides were first baked at 37°C overnight and
deparaffinized in xylene, then rehydrated in graded
ethanol. High-temperature antigen retrieval was performed
in a 10 mmol/L boiling sodium citrate buffer at pH 6.0 for
15 min. The slides were cooled to room temperature and
then immersed in 3% hydrogen peroxide for 30 min to
block endogenous peroxidase activity, and incubated in
10% normal goat serum for 30 min to reduce nonspecific
binding. Excess blocking solution was discarded, the
sections were incubated with monoclonal mouse anti-
human USP9X antibody (diluted 1:150, NBP2-03824,
NOVUS Biologicals) at 4°C overnight. The sections
were first washed with PBS and then incubated with
biotinylated secondar (SP-9002, Zhongshan Golden
Bridge Inc., China) for 60 min at room temperature.
Slides were then treated with streptavidin peroxidase
for 60 min at room temperature, followed by incuba-
tion with DAB (3, 3’-diaminobenzidine solution). Cells
with brown staining in the cytoplasm were considered
positive. The slides were then counter-stained with
hematoxylin and mounted with neutral balsam. Addition-
ally, sections incubated with normal serum blocking.
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blank controls, confirming any nonspecific staining.
Evaluation of USP9X protein expression
For evaluation of USP9X protein expression, a reprodu-
cible semiquantitative method that takes both staining
intensity (0, negative; 1, weak; 2, moderate and 3, strong)
and percentage of positive cancer cells (0, none; 1, <10%; 2,
10–50%; 3, 51 –80%; 4, > 80%) into account was adopted.
The final score was calculated by adding scores for per-
centage and intensity of positive cells. Scores of 0 ~ 3 were
defined as “negative expression” (-), scores of 4 ~ 5 as
“weakly positive expression” (+), and scores of 6 ~ 7 as
“strongly positive expression” (++) [7]. Additionally, overall
scores were divided into two groups: low expression (0-5)
and high expression (6 –7) in ESCC samples.
Statistical analysis
The association of clinicopathologic characteristics with
USP9X expression status was analyzed by the Pearson’s
χ2 test or Fisher’s exact test for categorical variables.
The Kaplan–Meier method and the log-rank test were
performed to assess the cumulative survival rate. Univar-
iate and multivariate Cox proportional hazard models
were used to estimate the relationship between USP9X
expression and clinical characteristics to overall survival.
Variables for multivariate analysis were selected by meansFigure 1 Immunohistochemical staining of USP9X expression in the p
tissue sections were stained using an immunoperoxidase method, as descr
shown: A In normal esophageal epithelium, immunostaining for weak USP9X
neoplasia (left side), positive staining was observed in most of the hete
epithelium. The USP9X expression increased gradually in the transformation f
neoplasia as carcinoma in situ in which the full-thickness epithelium showed
immunostaining for USP9X was presented in the cytoplasm of most of the caof a stepwise forward selection method. All analyses were
performed by SPSS 13.0 software (SPSS Inc., Chicago,
USA). P values of less than 0.05 were considered statisti-
cally significant.
Results
USP9X expression in normal esophageal squamous
epithelia, intraepithelial neoplasia, and ESCC detected by
immunohistochemistry
As shown in Figure 1, positive immunostaining for
USP9X could be observed in a cytoplasmic pattern. In
normal epithelium, weak positive signals were seen only
in the basal layer and some of the lower spinous layer in
the epithelium, whereas in precursor lesions positive
staining was observed in most of the heterogeneous cells
of the epithelium (Figure 1A,B). We also noticed that
the USP9X expression increased gradually in the trans-
formation from low grade intraepithelial neoplasia to
high grade intraepithelial neoplasia as carcinoma in situ
in which the full-thickness epithelium showed intensive
immunostaining for USP9X (Figure 1B). Moreover, most
of ESCC showed diffusely strong positive immunostain-
ing of USP9X (Figure 1C,D).
USP9X expression in normal esophageal squamous
epithelium, different precursor lesions and ESCC was
summarized in Table 1. As much as 96.0% of normal tis-
sue samples were detected with USP9X expression at arogression from normal epithelium to ESCC. Paraffin-embedded
ibed in Materials and methods. Representative images (200×) are
signal was found only in the basal layer. B In low grade intraepithelial
rogeneous cells from the basal layer to the granular layer of
rom low grade intraepithelial neoplasia to high grade intraepithelial
diffuse immunoreactivity for USP9X (right side). C, D In ESCC, intense
ncer cells.
Table 1 Summary of immunohistochemical expression of
USP9X in different lesions
Group USP9X staining Value
- (%) + (%) + + (%) Pa Pb Pc Pd








8 (22.9) 17 (48.6) 10 (28.6)
Cancer 10 (9.8) 51 (50.0) 41 (40.2) 0.37 0.01 0.12 <0.001
aEsophageal normal epithelia VS. low grade intraepithelial neoplasia.
bLow grade intraepithelial neoplasia VS. high grade intraepithelial neoplasia.
cHigh grade intraepithelial neoplasia VS. ESCC.
dEsophageal normal epithelia VS. ESCC.








≤59 60 24 (40.0)
≥60 42 17 (40.5)
Gender 0.928
Male 85 34 (40.0)
Female 17 7 (41.2)
Location 0.763
Upper 6 2 (33.3)
Middle 75 29 (38.7)
Lower 21 10 (47.6)
Tumor length 0.717
≤5 cm 60 25 (41.7)
>5 cm 42 16 (38.1)
Histological grades 0.123
G1a 22 13 (59.1)
G2a 58 20 (34.5)
G3a 22 8 (36.4)
Depth of invasion 0.046
T1-T2 57 18 (31.6)
T3-T4 45 23 (51.1)
Lymph node metastasis 0.032
Positive 49 25 (51.0)
Negative 53 16 (30.2)
TNM stage 0.112
I-II 57 19 (33.3)
III-IV 45 22 (48.9)
aG3, well-differentiated carcinoma; G2, moderately-differentiated carcinoma;
G1, poorly-differentiated carcinoma.
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USP9X expression was 40.2%. The expression of USP9X
was found significantly different between ESCC and
the normal mucosa (P < 0.001). However, both between
normal mucosa and low grade intraepithelial neoplasia
(P = 0.369), and between high grade intraepithelial
neoplasia and ESCC (P = 0.115), no significance was
detected in the high expression of USP9X. Neverthe-
less, there was a significance in USP9X expression be-
tween low grade intraepithelial neoplasia and high
grade intraepithelial neoplasia (P = 0.012). Moreover, a
gradual increase of positive rate in high USP9X protein
staining from normal (4.0%) to precancerous (low grade
intraepithelial neoplasia: 10.5%, high grade intraepithelial
neoplasia: 28.6%) and carcinoma tissues (40.2%) was
clearly detected, demonstrating that USP9X protein ex-
pression might indicate the progress of ESCC.
Correlation between USP9X expression and ESCC
Clinicopathological parameters
As shown in Table 2, ESCC samples with high-expression
of USP9X had significantly higher frequencies of T3–T4
cases compared with the low-expression group (51.1% vs.
31.6%, respectively; P = 0.046) and high expression of
USP9X was more prevalent in node-positive than in node-
negative cases (51.0% vs. 30.2%, respectively; P = 0.032).
TNM stage did not reach any statistical significance with
USP9X expression; however, it displayed a clear trend
(P = 0.112). We also observed a trend between USP9X
expression and histological grade, although this was
not statistically significant (P = 0.123).
Survival analysis and prognostic significance of USP9X
expression in ESCC
Survival analysis was conducted through Kaplan–Meier
curves for general survival. The overall survival rate of
patients with high USP9X expression was significantly
lower than that of patients with low USP9X expression.The 5-year overall survival rate of the high-expression
group was 31.2%, compared to 55.4% in the low-expression
group. Moreover, the 10-year survival rate of patients
with high USP9X expression was 14.2%, compared to
46.5% in patients with low USP9X expression (P =
0.001; Figure 2).
Further, in a univariate Cox regression analysis in
ESCC patients, the poor overall survival correlated
with depth of invasion (HR 1.740, P = 0.033), regional
lymph node metastasis (HR 1.910, P = 0.015), TNM stage
(HR 1.842, P = 0.018) and USP9X expression (HR 2.192,
P = 0.002). Moving ahead with the multivariate ana-
lysis, we noted that both TNM stage (HR 1.702, P =
0.042) and USP9X expression (HR 2.066, P = 0.005)
remained significantly associated with overall survival
(Table 3).
These findings showed that high expression of USP9X
is associated with shorter survival in ESCC patients and
indicated as an independent prognostic factor.
Figure 2 Relationship between USP9X expression status and cumulative survival in ESCC (n = 102). The 5-year survival rate of patients
with high USP9X expression was 31.2%, compared to 55.4% for patients with low USP9X expression (P = 0.001).
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Esophageal squamous cell cancer is one of the most
aggressive and deadly tumors in solid oncology. Despite
major advances in the therapeutic approach to this
disease, the crude mortality rate of esophageal cancer
remained with a 5-year survival rate of 10% to 20%
[19]. One of the reasons for its poor prognosis is that
ESCC is difficult to diagnose at an early stage [20].
Therefore, it would be of great clinical benefit if the pre-
cursor lesions of ESCC could be detected early through
potential biomarkers to promote the survival [21]. In clin-
ical pathology, the precursor lesions of ESCC are thought
to consist of various morphological stages: mild dysplasia,Table 3 Statistical analysis of cancer-specific survival of ESCC
Factor Univaria
HR (95% CI)
Age (≤59 vs. ≥60) 0.963 (0.573-1.617
Gender (male vs. female) 0.982 (0.498-1.936
Tumor length (≤5 cm vs. >5 cm) 1.002 (0.603-1.665
Histological grades (G3 vs. G2 vs. G1) 1.151 (0.801-1.654
Depth of invasion (T1-T2 vs. T3-T4) 1.740 (1.047-2.892
Lymph node metastasis (negative vs. positive) 1.910 (1.137-3.209
TNM stage (I-II vs. III-IV) 1.842 (1.109-3.062
USP9X expression (low vs. high) 2.192 (1.322-3.634
HR hazard ratio, CI confidence interval.moderate dysplasia, severe dysplasia and carcinoma in
situ. The mild dysplasia and moderate dysplasia are also
called low grade intraepithelial neoplasia, while severe
dysplasia and carcinoma in situ are defined as high grade
intraepithelial neoplasia [7,22]. We speculate that some
biological events that account for the malignancy and de-
velopment of ESCC, and some molecules could be identi-
fied as prognostic biomarkers in precursor lesions.
USP9X is excessive in tumor tissues such as follicular
lymphoma [15], colon adenocarcinomas and lung can-
cers [17] compared to the normal human tissues and
has an impact on tumor progression. In the present
study, we demonstrated the up-regulation of USP9Xpatients (n = 102)
te analysis Multivariate analysis





) 0.03 — 0.36
) 0.02 — 0.43
) 0.02 1.702 (1.020-2.838) 0.04
) 0 2.066 (1.242-3.437) 0.01
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for the first time. We observed that USP9X expression
was significantly higher in ESCC (90.2%) than that in nor-
mal epithelium (28%). Furthermore, level of high USP9X
expression increased gradually in the transformation from
normal epithelium (4.0%), low grade intraepithelial neo-
plasia (10.5%), high grade intraepithelial neoplasia (28.6%),
to invasive ESCC (40.2%). Although there was no differ-
ence between the high expression of USP9X in normal
mucosa and low grade intraepithelial neoplasia (P = 0.369),
nor between high grade intraepithelial neoplasia and
ESCC (p = 0.115), significance was detected in USP9X
expression between low grade intraepithelial neoplasia
and high grade intraepithelial neoplasia (p = 0.012).
Thus, we supposed USP9X correlated with the progres-
sion of ESCC and up regulation of USP9X might be a late
event in the multistep pathogenesis of ESCC, because
55.3% of low grade intraepithelial neoplasia were not
detected with USP9X expression, whereas 77.2% of high
grade intraepithelial neoplasia had positive expression of
USP9X (P = 0.012). The abnormal regulation and control
of cell cycle in the basal layer cells of the epithelium often
resulted in the earliest malignant lesion of the esophagus
[23,24]. Interestingly, the most intensive staining for
USP9X was usually observed in the basal and lower spin-
ous layers of the esophageal epithelium with precursor
lesions in our study. These probably indicated that up-
regulation of USP9X plays an important role in formation
and progress of precancerous lesions in ESCC, suggesting
USP9X could be a potential biomarker for ESCC.
As is well known, the prognosis and choice of therapy
for ESCC patients are determined primarily by the stage
of disease [25]. Moreover, lymph-node metastasis has
been reported to be an important negative prognostic
indicator of ESCC and was often related to the depth
of invasion [26,27]. In this study, we observed that
USP9X expression status was well-associated with
depth of invasion (p = 0.046) and lymph node metastasis
(p = 0.032). Nevertheless, no statistical significance was
found between USP9X expression and histological grade
(p = 0.123) or TNM stage (p = 0.112) in ESCC, al-
though it displayed a clear trend. Maybe the uneven
distribution of patients in different histological grades
and TNM stages biased the results. We further evaluated
the prognostic value of USP9X in ESCC. The results
showed that increased USP9X expression was signifi-
cantly correlated to a lower survival rate in patients
after radical surgery (P = 0.001). Importantly, TNM
stage (HR 1.702, P = 0.042) and USP9X expression
(HR 2.066, P = 0.005) were revealed as independent
predictors of prognosis according to multivariate Cox
regression analysis. Thus, USP9X could be considered
as a potential diagnosis and prognostic predictor for
ESCC.Recent studies have addressed the possible relation be-
tween USP9X expression and clinicopathologic factors
in human tumors. Interrogation of public expression da-
tabases [28,29] has shown that increased USP9X mRNA
in tumors could significantly anticipate poor outcome
for multiple myeloma patients. MCL1, one member of
pro-survival BCL2 family, is rapidly turned over through
the action of ubiquitin ligases [30,31]. Martin Schwickart
et al. then indicated that interaction of USP9X and
MCL1 is of prognostic relevance for several human ma-
lignancies including multiple myeloma [15]. They used
USP9X knockdown in combination with ABT-737, a
small molecule antagonist of the pro-survival proteins
not including MCL1 to test increased apoptosis in tumor
cells. They found USP9X knockdown alone caused a
modest decrease in tumour growth but specifically stabi-
lized MCL1 by removing its degradative Lys 48-linked
polyubiquitin chains to promoting cell survival. How-
ever, another observation found that low USP9X protein
and messenger RNA expression in pancreatic ductal
adenocarcinoma (PDA) were inversely associated with
poor survival after surgery [32]. What is more, obvious
changes in Mcl1 protein levels could not be detected
upon Usp9x loss in PDA. Maybe these opposing findings
could be explained by the tissue-specificity of USP9X in
different tumors. As the malignant development of dif-
ferent cell types may be somewhat different, the carcino-
genesis of USP9X in different tissues also had its own
characteristics. In this study, our results provided the
first evidence that USP9X expression was associated
with the progression and poor outcome in ESCC. How-
ever, further studies are necessary to precisely identify
the molecular mechanisms.
Conclusion
The present study offered clinical evidence for the first
time that USP9X expression is well correlated to ESCC
progression, aggressive behaviors and poor prognosis.
Therefore, we envision that USP9X may be a novel tumor
marker, a prospective prognostic indicator and a potential
therapeutic target for ESCC.
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